FDG-PET in prediction of splenectomy findings in patients with known or suspected lymphoma
Sarah C. Rutherford(NewYork–Presbyterian Hospital), John P. Leonard(New York University), Amy Chadburn(Cornell University), Thomas J. Fahey(NewYork–Presbyterian Hospital), Rubén Niesvizky(Cornell University), Rebecca Elstrom(Acentech (United States)), Morton Coleman(Cornell University), Biree Andemariam(UConn Health), Shibu M. Philips(Wadsworth Center), Richard R. Furman(Cornell University), Stanley J. Goldsmith(United States Department of Health and Human Services), Peter Martin(Northwestern University)
Cited by 19
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k